European Federation of Pharmaceutical Industries and Associations

Recent papers from European Federation of Pharmaceutical Industries and Associations

1. An Exploratory Study of Electrophotonic Analysis in Size-6 Pilules Impregnated with Stepwise Dilutions of Cuprum metallicum and Gelsemium sempervirensChemosensors · 2026
2. Vaccines as Global Health Security Infrastructure: Insights from a Descriptive Analysis of Vaccines Europe Members’ Clinical PipelinesVaccines · 2026
3. Safe and Sustainable by Design (SSbD) landscape: Mapping state of the art approaches along the innovation process and developing good practicesSustainable Chemistry and Pharmacy · 2026
4. Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paperJournal of Pediatric Gastroenterology and Nutrition · 2025
5. Dietary administration of α-terpineol to Sprague-Dawley rats for 90 daysRegulatory Toxicology and Pharmacology · 2025
6. Assessment of health and science undergraduate students’ knowledge, attitudes, education and training related to antibiotic use and antimicrobial resistance in 27 EU/EEA universitiesAccess Microbiology · 2025
7. Enhanced anaerobic degradation of 2,4,6-trichlorophenol through electrochemical advanced oxidation pretreatmentJournal of Water Process Engineering · 2025
8. Reliance into ActionTherapeutic Innovation & Regulatory Science · 2025
9. The Brussels International Declaration on Lipoprotein(a) Testing and ManagementAtherosclerosis · 2025
10. EU roadmap for phasing out animal testing for chemical safety assessments: Recommendations from a multi-stakeholder roundtableALTEX · 2025
11. A vision to the future: value-based laboratory medicineClinical Chemistry and Laboratory Medicine (CCLM) · 2024
12. The Rare Disease Moonshot: Paradigms Shift, Translational Medicine, and Regulatory Science for the World's Rarest ConditionsClinical Pharmacology & Therapeutics · 2024
13. The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology AssessmentValue in Health · 2024
14. Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticalsRegulatory Toxicology and Pharmacology · 2024
15. From setbacks to success: lessons from the journey of RSV vaccine developmentTherapeutic Advances in Vaccines and Immunotherapy · 2024
16. Achieving consensus on the language of obesity: a modified Delphi studyEClinicalMedicine · 2023
17. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018–2019Journal of Cancer Policy · 2023
18. Using Science as a Tool to Shape Political Opinion2023
19. Role of innovation in pharmaceutical regulation: A proposal for principles to evaluate EU General Pharmaceutical Legislation from the innovator perspectiveDrug Discovery Today · 2023
20. The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remainRegulatory Toxicology and Pharmacology · 2023